首 页
医药产品
医保药品
中标目录
医药招标
数据中心
医学资料
医药新闻
医药展会
OTC药品
保健品
医疗器械
处方药
专科药
中医药
器械中标目录
药品批发行情
求购信息
医药下载
药价简讯
当前位置:药药网 / 数据中心 / 临床注释,变异和临床注释数据
喹硫平
临床注释ID
1451147720
药物名称(英)
quetiapine
变异单倍型
CYP3A4*1, CYP3A4*20, CYP3A4*22
基因
CYP3A4
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Metabolism/PK
表现型类别
代谢/PK
分数
102.0
PMID计数
2
计数的证据
3
表现型
表现型(英)
最新日期
2022-03-18
URL
https://www.pharmgkb.org/clinicalAnnotation/1451147720
专业人口(英)
专业人口
临床等位基因
id
等位基因
注释文本
212
*22
Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.
211
*20
Patients carrying two copies of the CYP3A4*20 allele or one copy of the *20 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.
210
*1
Patients with two copies of the CYP3A4*1 allele may have decreased exposure to quetiapine as compared to patients with two copies of the *20 or *22 alleles or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.
临床证据
id
证据的ID
总结
14491
1451648462
CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.
14490
1451147640
CYP3A4 *3 + *20 + *22 are associated with increased exposure to fentanyl, imatinib or quetiapine in healthy individuals as compared to CYP3A4 *1.
14489
PA166265421
Annotation of DPWG Guideline for quetiapine and CYP3A4
临床病史
id
类型
评论
492
Update
Second curator check (KS)
314
Update
CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
313
Create
Created
273
Update
Added DPWG guideline. Rewrote phenotype descriptions. Moved *3 to a new CA as this is not covered by the guideline.
最新招商产品
更多>>
网站地图
-
网站开发
-
网站简介
-
会员服务
-
法律声明
-
联系我们
-
药品招商频道
-
药品信息排行
-
2018年版国家基本药物目录
-
意见反馈
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:
国家药品监督管理局
|
国家中医药管理局
|
SDA药品评审中心
|
医加医疗器械
|
膏药生产厂家
|
爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究 客服热线:0575-83552251 / 13754370441 QQ客服:
浙ICP备16010490号-2
增值电信业务经营许可证:
浙B2-20220931
互联网药品信息服务资格证书编号:
(浙)-经营性2023-0215
浙公网安备:33068302000535
医药代理商群1:
医药代理商群2:
医药代理商群3: